Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 22

Trial Status

Completed2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT00023764Phase 2Completed
Bortezomib in Treating Patients With Lymphoproliferative Disorders
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular Lymphoma+1 more
Principalinvestigator
NCT01326702Phase 1/2Completed
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Adult B Acute Lymphoblastic LeukemiaAdult Nasal Type Extranodal NK/T-Cell LymphomaAdult Solid Neoplasm+35 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Thomas E. Witzig, MD

Mayo Clinic

Related
12 trials

Shared therapeutic areas:

Lymphoma, Large-Cell, AnaplasticAngioimmunoblastic T-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score4%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular Lymphoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellWaldenstrom Macroglobulinemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Recurrent Mantle Cell LymphomaWaldenstrom Macroglobulinemia
Similarity Score2%

Agostino Tafuri

AOU Sant'Andrea

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score1%

Laura Nocilli

Ospedale Papardo

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score1%

Vincenzo Fraticelli

Responsible Research Hospital

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score1%

Roberta Murru

Ospedale Oncologico" A. Businco" - ARNAS "G. Brotzu"

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score1%

Luca Laurenti

Policlinico Universitario Gemelli IRCCS

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score1%

Hagop Youssoufian, MD

Verastem, Inc.

Related
20 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT00023764Phase 2PrincipalInvestigator

Bortezomib in Treating Patients With Lymphoproliferative Disorders

Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular Lymphoma+1 more
Completed
NCT01326702Phase 1/2PrincipalInvestigator

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Adult B Acute Lymphoblastic LeukemiaAdult Nasal Type Extranodal NK/T-Cell LymphomaAdult Solid Neoplasm+35 more
Completed

All 2 trials loaded